



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

*20 April 2001*

TOWNSEND and TOWNSEND and CREW LLP

By:

*Malinda Odegit*

**PATENT**  
Attorney Docket No.: 015280-315100US  
Client Reference No.: E-094-97/0

**RECEIVED**

APR 26 2001

TECH CENTER 1600/2900

*GP 1642*

*Box Seq. listing*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

CHANDRASEKHARAPPA *et al.*

Application No.: 09/380,337

Filed: March 6, 2000

For: *MEN1*, THE GENE ASSOCIATED  
WITH MULTIPLE ENDOCRINE  
NEOPLASIA TYPE 1, MENIN  
POLYPEPTIDES AND USES THEREOF

Examiner: Hunt, Jennifer

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed March 22, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.